Cognition Therapeutics (CGTX)

• Market cap: $27.5M
• 1 day: -3.33%
• 5 days: -5.53%
• 1 month: -10.30%
• 3 months: -42.14%
• 6 months: 8.29%
• Year to date: -38.60%
• 1 year: -75.74%
• 5 years: -96.52%
• 10 years: -96.52%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Employees: 25

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

300% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 2

290% more capital invested

Capital invested by funds: $1.99M [Q3] → $7.76M (+$5.77M) [Q4]

22% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 9

16.04% more ownership

Funds ownership: 10.6% [Q3] → 26.65% (+16.04%) [Q4]

13% more funds holding

Funds holding: 40 [Q3] → 45 (+5) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $5 1,026% upside
• Avg. target: $6.50 1,364% upside
• High target: $8 1,702% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Raghuram Selvaraju 39% 1-year accuracy 134 / 343 met price target	1,026% upside $5	Buy Maintained	24 Mar 2025
Chardan Capital Daniil Gataulin 39% 1-year accuracy 17 / 44 met price target	1,702% upside $8	Buy Maintained	21 Mar 2025